LOGIN  |  REGISTER
Astria Therapeutics
Recursion

Sharecare to report fourth quarter and full year fiscal 2023 financial results on Wednesday, March 13

February 22, 2024 | Last Trade: US$1.43 0.00 0.00

ATLANTA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that it will report fourth quarter and full year fiscal 2023 financial results on Wednesday, March 13, 2024, before the market opens. In conjunction, the company will host a conference call to review results at 8:00 a.m. EDT on the same day.

Conference Call Details

The conference call can be accessed by dialing (833) 636-1352 for U.S. participants, or (412) 902-4148 for international participants, and asking to be joined into the Sharecare call; or via live audio webcast, available online at https://investors.sharecare.com.

A webcast replay of the call will be available for on-demand listening at the same link and will remain available for approximately 90 days.

About Sharecare

Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page